These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37943779)

  • 21. PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study.
    Chen S; Wei H; Zhao W; Jiang W; Ning R; Zhou S; Tan L; Wang H; Su C; He J; Zeng A; Zhao Y; Yu Q
    Front Immunol; 2022; 13():1059995. PubMed ID: 36569915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-1/L1 inhibitors may increase the risk of pericardial disease in non-small-cell lung cancer patients: a meta-analysis and systematic review.
    Li H; Han D; Zhang L; Feng X; Li H; Yang F; Song L; Li X
    Immunotherapy; 2022 May; 14(7):577-592. PubMed ID: 35373580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment.
    Chang CY; Lai YC; Wei YF; Chen CY; Chang SC
    Onco Targets Ther; 2021; 14():2301-2309. PubMed ID: 33833528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atypical Response in Metastatic Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: Radiographic Patterns and Clinical Value of Local Therapy.
    Jiang S; Zhang J; Chu L; Chu X; Yang X; Li Y; Guo T; Zhou Y; Xu D; Mao J; Zheng Z; An Y; Sun H; Dong H; Yu S; Ye R; Hu J; Chu Q; Ni J; Zhu Z
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
    Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS
    Cancer; 2018 Jan; 124(2):271-277. PubMed ID: 28960263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.
    Chen S; Mo W; Jiang W; Zhou S; Gan H; Yu Q
    Front Immunol; 2023; 14():1218258. PubMed ID: 37614237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
    Saxena P; Singh PK; Malik PS; Singh N
    Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Makrakis D; Rounis K; Tsigkas AP; Georgiou A; Galanakis N; Tsakonas G; Ekman S; Papadaki C; Monastirioti A; Kontogianni M; Gioulbasanis I; Mavroudis D; Agelaki S
    PLoS One; 2023; 18(2):e0277708. PubMed ID: 36763597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism.
    Yin J; Wu Y; Yang X; Gan L; Xue J
    Front Immunol; 2022; 13():830631. PubMed ID: 35464480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.
    Tajarernmuang P; Ofiara L; Beaudoin S; Wang H; Benedetti A; Gonzalez AV
    Chest; 2021 Aug; 160(2):743-753. PubMed ID: 33675792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
    Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
    Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
    Mok TSK; Wu YL; Kudaba I; Kowalski DM; Cho BC; Turna HZ; Castro G; Srimuninnimit V; Laktionov KK; Bondarenko I; Kubota K; Lubiniecki GM; Zhang J; Kush D; Lopes G;
    Lancet; 2019 May; 393(10183):1819-1830. PubMed ID: 30955977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correction: Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis.
    Schad F; Thronicke A; Steele ML; Merkle A; Matthes B; Grah C; Matthes H
    PLoS One; 2022; 17(8):e0273387. PubMed ID: 35972953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
    Brahmer JR; Lee JS; Ciuleanu TE; Bernabe Caro R; Nishio M; Urban L; Audigier-Valette C; Lupinacci L; Sangha R; Pluzanski A; Burgers J; Mahave M; Ahmed S; Schoenfeld AJ; Paz-Ares LG; Reck M; Borghaei H; O'Byrne KJ; Gupta RG; Bushong J; Li L; Blum SI; Eccles LJ; Ramalingam SS
    J Clin Oncol; 2023 Feb; 41(6):1200-1212. PubMed ID: 36223558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Corrigendum: MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment.
    Song N; Li P; Song P; Li Y; Zhou S; Su Q; Li X; Yu Y; Li P; Feng M; Zhang M; Lin W
    Front Cell Dev Biol; 2020; 8():746. PubMed ID: 32974332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer.
    Ghiringhelli F; Bibeau F; Greillier L; Fumet JD; Ilie A; Monville F; Laugé C; Catteau A; Boquet I; Majdi A; Morgand E; Oulkhouir Y; Brandone N; Adam J; Sbarrato T; Kassambara A; Fieschi J; Garcia S; Lepage AL; Tomasini P; Galon J
    EBioMedicine; 2023 Jun; 92():104633. PubMed ID: 37244159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative Study of PD-L1 Expression in Different Sites of 
Non-small Cell Lung Cancer].
    Huang X; Wu J; Zhou L; Song Z; Xu W; Jia L; Diao X; Wu Q; Lin D
    Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):303-310. PubMed ID: 35570146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.